Peptide product documentation often includes a sequence written as a line of letters or three-letter residue names. That compact notation is useful, but it is only one part of a complete material description. Laboratories comparing a specification, a label and a certificate of analysis (COA) should understand what the sequence communicates—and what it leaves unresolved.
Read the sequence in the stated direction
By convention, a linear peptide sequence is written from the amino terminus (N-terminus) on the left to the carboxyl terminus (C-terminus) on the right. A sequence such as Ala-Gly-Ser therefore gives an order, not merely a list of ingredients. Reversing that order describes a different chain. In one-letter notation, the same illustrative sequence is AGS. The abbreviations follow the IUPAC–IUBMB recommendations for amino-acid and peptide nomenclature.
When checking a supplier document, compare the full sequence rather than relying on a shortened product name. One missing, added or substituted residue can change the identity of the material. A clear sequence record also helps a laboratory match the requested material to its own reference files and analytical method.
One-letter and three-letter codes
One-letter codes are compact and convenient for longer sequences. Three-letter codes, such as Ala for alanine, Gly for glycine and Ser for serine, can be easier to read when a short peptide contains unfamiliar residues or modifications. Neither style is automatically more authoritative: the document should be internally consistent and define any non-standard symbols.
A practical review asks whether the sequence on the specification matches the label, purchase record and batch-specific paperwork. If a code is ambiguous or a residue is not defined, request clarification before treating two documents as equivalent. Do not fill gaps by guessing from a product nickname.
Termini and chemical modifications matter
The letters in a sequence do not necessarily describe the whole molecule. A peptide may have a modified N-terminus or C-terminus, a non-standard amino acid, a cyclized structure or another stated modification. Such details should be recorded explicitly in the specification. Two materials with the same core residue order but different terminal forms need not be analytically interchangeable.
The expected molecular mass also depends on the exact chemical form being described. For that reason, a laboratory should not calculate a mass from the bare letter sequence and assume it must match every supplier document. Instead, reconcile the sequence, terminal groups, salt or counter-ion information where relevant, and the supplier’s stated analytical basis. Our guide to HPLC and mass spectrometry in peptide quality documentation explains why identity and chromatographic purity answer different questions.
Sequence is not the same as confirmed identity
A printed sequence is a claim about the intended material; it is not, by itself, proof that the contents of a vial match that claim. Batch-linked analytical documentation helps assess whether the supplied material is consistent with the specification. The relevant methods and acceptance criteria depend on the material and intended laboratory work.
Check whether the COA identifies the batch, the analytical method, the reported result and any limitations. A useful document should make it possible to connect the result to the actual lot received. See our research peptide COA guide for a broader document-review checklist.
A simple document-comparison workflow
- Confirm the full name and sequence. Compare the specification with the order and label, reading from N-terminus to C-terminus.
- Record every stated modification. Include terminal groups, non-standard residues and structural notes rather than copying only the core letters.
- Match the batch identifier. The label and COA should point to the same lot or have an explained traceability link.
- Review analytical evidence. Identify which tests support identity and which report other properties, such as chromatographic purity.
- Resolve discrepancies in writing. Ask the supplier to clarify undefined symbols, conflicting masses or inconsistent naming before the material enters a study.
Keep the record useful for future work
A consistent internal record can include the original supplier notation, a laboratory-approved normalized sequence, the complete chemical-form description, lot number, received date and links to the relevant documents. Preserve the original files as well as any interpretation: later reviewers should be able to see what the supplier actually stated. This supports reproducibility and reduces confusion when comparing lots or repeating an analysis.
For the underlying notation, consult the IUPAC–IUBMB recommendations on amino acids and peptides. Their conventions provide a shared language, while batch-specific evidence and a clear specification remain essential for material review.
For research purposes only. Not for human consumption. This article is educational and does not provide medical or use instructions.
Confirm the identity behind a product name
Product names are starting points for a documentation enquiry. Request the exact sequence, modifications and batch-specific identity information for the material being evaluated.
[…] These are possibilities, not predictions. The local sequence, pH, dissolved oxygen, light, trace metals, temperature, and formulation all influence what is observed. Terminal modifications and counterions can matter too. Researchers should therefore begin with the complete molecular description, as discussed in our guide to reading peptide sequences and modifications. […]